Oncology (all articles)
Guidelines for diagnosing incidental solitary bone lesions on CT and MRI in adults: bone reporting and data system (Bone-RADS).
4 Apr, 2022 | 00:45h | UTC
Commentary on Twitter (article and images under a http://creativecommons.org/licenses/by-nc/4.0/)
https://twitter.com/AdamSingerMD/status/1509949481969668098
Study finds no increased risk of brain tumors for mobile phone users.
1 Apr, 2022 | 10:04h | UTCNews Release: No increased risk of brain tumours for mobile phone users, new study finds – University of Oxford
Original Study: Cellular Telephone Use and the Risk of Brain Tumors: Update of the UK Million Women Study – JNCI: Journal of the National Cancer Institute
Long-term follow-up of RCT: Nivolumab plus chemotherapy or ipilimumab in gastro-esophageal cancer.
1 Apr, 2022 | 08:37h | UTCNivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer – Nature
Commentary on Twitter
New data from CheckMate 649 confirm that the OS benefit of nivolumab added to chemotherapy for advanced-stage gastroesophageal adenocarcinoma persists beyond 24 mo (HR 0.79; 95% CI 0.71-0.88); however, nivo+ipi did not improve OS vs chemotherapy alone: https://t.co/2Pom4zD7oX
— NatureRevClinOncol (@NatRevClinOncol) March 25, 2022
Evidence-based guideline recommendations on multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer.
1 Apr, 2022 | 08:30h | UTC
Practice review: Evidence-based and effective management of anemia in palliative care patients.
1 Apr, 2022 | 08:21h | UTC
Practice review: Evidence-based and effective management of fatigue in patients with advanced cancer.
1 Apr, 2022 | 08:26h | UTC
Review: The use of virtual care in patients with hematologic malignancies.
1 Apr, 2022 | 08:18h | UTC
Study Commentary: Older women with breast cancer chose less aggressive treatment when they used a decision aid.
1 Apr, 2022 | 08:16h | UTC
Commentary on Twitter
Open access in May's BJS: Bridging the age gap in breast cancer: two decision support interventions for older women with operable breast cancer https://t.co/s70uEVyAxU @AmyLightnerMD @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @robhinchliffe1 @young_bjs pic.twitter.com/IUuiUldUTS
— BJS (@BJSurgery) June 11, 2021
Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study.
31 Mar, 2022 | 08:23h | UTCEditorial: Screening high risk populations for lung cancer
News Release: US lung cancer screening linked to earlier diagnosis and better survival – British Medical Journal
Related:
Screening for Lung Cancer: CHEST Guideline and Expert Panel Report.
Commentary on Twitter
Increases in the early detection of lung cancer since 2014 in the US have saved an estimated 10,100 lives, but screening rates are still extremely low and disparities in access to lung cancer screening continue to exist, say researchers https://t.co/j58LfcGCKU
— The BMJ (@bmj_latest) March 31, 2022
Global burden of cutaneous melanoma in 2020 and projections to 2040.
31 Mar, 2022 | 08:11h | UTCGlobal Burden of Cutaneous Melanoma in 2020 and Projections to 2040 – JAMA Dermatology (free for a limited period)
Editorial: Melanoma Epidemiology—Pivoting to Low- and Middle-Income Countries (free for a limited period)
Commentary: Global Burden of Melanoma Considerable, Set to Rise by 2040 – HealthDay
Guidance on the need for contraception related to use of pharmaceuticals: providing information on the proper use of pharmaceuticals in patients with reproductive potential.
31 Mar, 2022 | 07:49h | UTC
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer.
31 Mar, 2022 | 07:48h | UTC
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer.
31 Mar, 2022 | 07:46h | UTC
SEOM clinical guideline: chemotherapy-induced nausea and vomiting.
31 Mar, 2022 | 07:45h | UTCSEOM clinical guideline emesis (2021) – Clinical and Translational Oncology
Related:
Prevention of Chemotherapy-induced nausea and vomiting in the older patient: optimizing outcomes.
EAU Guidelines on renal cell carcinoma.
30 Mar, 2022 | 10:19h | UTC
Cohort Study: Risk factors for complications after surgery for pancreatic neuroendocrine tumors.
30 Mar, 2022 | 10:03h | UTCRisk factors for complications after surgery for pancreatic neuroendocrine tumors – Surgery
Commentary on Twitter
Risk factors for complications after surgery for pancreatic neuroendocrine tumors@hpb_so @NANETS1 @AHPBA @EAHPBA @Cancer_UMCU @UMCU_Intl @me4_so
🆓#openaccess #VisualAbstract
https://t.co/uVNFRqpKKP pic.twitter.com/iIVbQSBawD— SURGERY Journal (@SurgJournal) March 25, 2022
Cohort Study: Characteristics and prognosis of acquired resistance to immune checkpoint inhibitors in gastrointestinal cancer.
30 Mar, 2022 | 08:47h | UTCInvited Commentary: Acquired Immunotherapy Resistance in Gastrointestinal Cancers – JAMA Network Open
Cumulative burden of psychiatric disorders and self-harm across 26 adult cancers.
29 Mar, 2022 | 09:58h | UTCCumulative burden of psychiatric disorders and self-harm across 26 adult cancers – Nature Medicine
See also: Suicide risk and mortality among patients with cancer – Nature Medicine (if the link is paywalled, try this one)
Invited Commentary: Shining a light on the psychological burden of cancer – Nature Medicine
Commentary on Twitter
Patients with cancer who are diagnosed with a psychiatric disorder had a higher incidence of mortality and are at greater risk of self-harm compared with other patients with cancer, according to a paper published in @NatureMedicine. https://t.co/U5b7ODKSNd pic.twitter.com/816N6ZCfms
— Nature Portfolio (@NaturePortfolio) March 28, 2022
Review: Acute kidney injury in critically ill patients with cancer.
29 Mar, 2022 | 09:47h | UTC
Commentary on Twitter
Advances in cancer therapy have improved patient survival; however, AKI is common in patients with cancer. This Review highlights the epidemiology of AKI in critically ill patients with cancer, risk factors for AKI, & common pathologies linked to therapies https://t.co/AVUvGCqqwh pic.twitter.com/1GdM3P0h3j
— CJASN (@CJASN) March 28, 2022
Review: The emerging role of photoacoustic imaging in clinical oncology.
29 Mar, 2022 | 08:24h | UTCThe emerging role of photoacoustic imaging in clinical oncology – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a Review now published online, Li Lin and Lihong Wang discuss the clinical applications of photoacoustic imaging in oncology research and practice https://t.co/ENESZ0ibOI pic.twitter.com/oukxtHvzsf
— NatureRevClinOncol (@NatRevClinOncol) March 24, 2022
Review | Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion.
28 Mar, 2022 | 08:47h | UTCPreparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion – Nature Reviews Clinical Oncology (if the link is paywalled, try this one)
Commentary on Twitter
In a new Review now online, @abouelem and co-authors discuss the preparation and management of patients with cancer before #CARTcells, an area in which evidence on optimal conditions needs to grow https://t.co/Sb6rgcOTTJ pic.twitter.com/wjRrPDpoT7
— NatureRevClinOncol (@NatRevClinOncol) March 23, 2022
RCT: Trastuzumab Deruxtecan vs. Trastuzumab Emtansine for breast cancer.
28 Mar, 2022 | 08:48h | UTCTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay
Commentary on Twitter
In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U
— NEJM (@NEJM) March 24, 2022
Cohort Study: Association of lower extremity lymphedema with physical functioning and activities of daily living among older survivors of colorectal, endometrial, and ovarian cancer.
28 Mar, 2022 | 08:39h | UTCCommentaries:
Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay
Commentary on Twitter
Cohort study found nearly 1/3 of older female survivors of #ColorectalCancer, #EndometrialCancer, or #OvarianCancer have lower-extremity lymphedema (LEL), which is associated with worse physical function and needing assistance with ADLs. https://t.co/806Tt88TuV
— JAMA Network Open (@JAMANetworkOpen) March 9, 2022
RCT: Effect of induction chemotherapy with Paclitaxel, Cisplatin, and Capecitabine vs. Cisplatin and Fluorouracil on failure-free survival for patients with stage IVA to IVB Nasopharyngeal Carcinoma.
28 Mar, 2022 | 08:36h | UTCEffect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (free registration required)
Commentary on Twitter
Phase 3 randomized trial of paitents with stage IVA to IVB nasopharyngeal carcinoma shows that induction chemotherapy w 2 cycles of paclitaxel/cisplatin/capecitabine improved failure-free survival vs. cisplatin/5-FU before concurrent chemoradiation. https://t.co/YYEvFsTxgd pic.twitter.com/7qbSXLWCE1
— JAMA Oncology (@JAMAOnc) March 24, 2022
Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study.
25 Mar, 2022 | 09:56h | UTCCommentaries:
Sweeteners may be linked to increased cancer risk – new research – The Conversation
Expert reaction to observational study of sweeteners and cancer risk – Science Media Centre